Aclipse Therapeutics is an innovative biopharmaceutical company that focuses on developing novel and highly differentiated drugs to address diseases with high unmet medical needs. Our strategy is reducing clinical development risk by combining a new and druggable understanding of disease pathways with a novel form of an existing drug that inhibits these pathways, allowing us to build upon existing nonclinical and clinical data while creating a significant patent barrier-to-entry.

‍

‍

The Science

Aclipse develops innovative drug products based on a combination of new understandings of disease pathways with a novel form of an existing drug that inhibits these pathways. This allows them to build upon existing nonclinical and clinical data while creating a significant patent barrier-to-entry.

THE M102 PROGRAM

The current main effort on innovative drug development focuses on the M102 program. M102 is a proprietary disease-modifying drug candidate based on recently understood disease pathways in neuro-generative diseases.

‍

‍

‍